Latest Breaking News On - Initiate phase - Page 1 : comparemela.com

JCR Pharmaceuticals : FY2023 Results Briefing Session -Material-（1,196KB）

JCR Pharmaceuticals : FY2023 Results Briefing Session -Material-（1,196KB）
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesHiroyuki sonodaAnne bechetPharmaceuticals co ltdWave of technology innovationResearch divisionBriefing sessionInitiate phaseDevelopmental pipelinesActing officerGeneral managerLatin americaTrack designationPediatric disease designationGlobal phaseOrphan drug designation

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesBrianm stremUniversity of californiaKiora pharmaceuticalsKiora pharmaceuticals incAssociation of researchCalifornia newsfile corpOpen innovationMelissa toscaInvestigational new drugInitiate phasePrivate securities litigation reform actAnnual reportCurrent assetsRelease assetsCurrent liabilities

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Helen rubinsteinHenry gosebruchExchange commissionNeumora therapeutics incTherapeutics reports first quarterProvides businessMajor depressive disorderFourth quarterInitiate phaseDisease agitationSecond quarterAllosteric modulatorAdvancing preclinical work acrossUnited kingdomNeumora therapeuticsPrivate securities litigation reform act

Genmab A/S : Interim Report for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended.

Genmab duobodyTivdak genmabAndrew carlsenInformationfor tivdakGenmab abbvieMarisol peronAbbvie incSociety of gynecologic oncologyExchange commissionPfizer incEuropean medicines agencyUs national comprehensive cancer networkCompany announcementMedarex incJanssen biotech incProfoundbio inc

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

WAKIX® Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively U.S. Food and Drug Administration Granted.

United statesUnited kingdomLuis sanayJeffreym daynoIdiopathic hypersomnia development program scheduled forParagon biosciencesEuropean medicines agencyDrug administrationEuropean unionZynerba pharmaceuticalsExchange commissionHarmony biosciences holdings incNet revenueFourth quarterFull yearRepresenting growth